Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

July 30, 2025 09:24 ET | Source: Trethera Corporation

FDA Provides Trethera Clearance to Initiate TRE-515 Clinical Trial in Healthy Volunteers to Study Food Effect and Biomarkers

Creates platform for precision dosing, companion diagnostics, streamlined development, and broader use across cancer and autoimmune diseases.
July 30, 2025 09:00 ET | Source: Muscular Dystrophy Association

Registration Now Open for the 2026 MDA Clinical & Scientific Conference Where Global Leaders in Neuromuscular Disease Research & Care Unite to Drive the Next Breakthroughs March 8-11 in Orlando, FL

New York, July 30, 2025 (GLOBE NEWSWIRE) -- The Muscular Dystrophy Association (MDA), leader and innovator of the largest global gathering of the neuromuscular disease community, announced today...
July 24, 2025 01:57 ET | Source: AB Science

AB Science a obtenu l'autorisation de plusieurs pays européens pour initier l’étude confirmatoire de phase 3 avec le masitinib dans la SLA

COMMUNIQUÉ DE PRESSE AB SCIENCE A OBTENU L'AUTORISATION DE PLUSIEURS PAYS EUROPÉENS POUR INITIER L’ETUDE CONFIRMATOIRE DE PHASE 3 AVEC LE MASITINIB DANS LA SCLEROSE LATERALE AMYOTROPHIQUE CETTE...
July 24, 2025 01:57 ET | Source: AB Science

AB Science has received approval from several European countries to initiate the confirmatory phase 3 study of masitinib in ALS

PRESS RELEASE AB SCIENCE HAS RECEIVED APPROVAL FROM SEVERAL EUROPEAN COUNTRIES TO INITIATE THE CONFIRMATORY PHASE 3 STUDY OF MASITINIB IN AMYOTROPHIC LATERAL SCLEROSIS THIS APPROVAL FOLLOWS PROTOCOL...
July 02, 2025 14:00 ET | Source: MIT Sloan School of Management

Financing Innovation: Proposal for Novel Adaptive Platform Trial Fund Offers New Model for ALS Drug Development

Cambridge, Mass., July 02, 2025 (GLOBE NEWSWIRE) -- A team of researchers from the MIT Sloan School of Management, the Sean M. Healey & AMG Center for ALS at Massachusetts General Hospital...
May 13, 2025 11:00 ET | Source: Athira Pharma, Inc.

Athira Pharma to Present Data from First-in-Human Phase 1 Clinical Trial of ATH-1105 at the 4th Annual ALS Drug Development Summit

Data from Phase 1 clinical trial of ATH-1105 in healthy volunteers showed a favorable safety and tolerability profile; dose proportional pharmacokinetics and CNS penetration support continued clinical...
May 09, 2025 16:05 ET | Source: Athira Pharma, Inc.

Athira Pharma Reports First Quarter 2025 Financial Results and Pipeline and Business Updates

Completed healthy volunteer Phase 1 clinical study of ATH-1105 as a potential treatment for amyotrophic lateral sclerosis (ALS); full healthy volunteer data expected in 2H25 On-track to enable...
May 05, 2025 12:03 ET | Source: AB Science

AB Science présentera lors de la réunion annuelle de l’ENCALS en 2025 de nouvelles données issues du programme de développement clinique du masitinib dans la SLA

COMMUNIQUE DE PRESSE AB SCIENCE PRÉSENTERA LORS DE LA RÉUNION ANNUELLE DE L'ENCALS EN 2025 DE NOUVELLES DONNÉES ISSUES DU PROGRAMME DE DEVELOPPEMENT CLINIQUE DU MASITINIB DANS LA SCLÉROSE LATÉRALE...
May 05, 2025 12:03 ET | Source: AB Science

AB Science will present new data from masitinib clinical program in ALS in two presentations at the 2025 ENCALS Annual Meeting

PRESS RELEASE AB SCIENCE TO PRESENT NEW DATA FROM MASITINIB CLINICAL PROGRAM IN AMYOTROPHIC LATERAL SCLEROSIS IN TWO PRESENTATIONS AT THE 2025 ENCALS ANNUAL MEETING MASITINIB REDUCES SERUM...
April 29, 2025 09:00 ET | Source: Muscular Dystrophy Association

Muscular Dystrophy Association Launches National ALS Awareness Campaign to Accelerate the Search for a Cure

New York, April 29, 2025 (GLOBE NEWSWIRE) -- The Muscular Dystrophy Association (MDA) today announced the launch of its nationwide campaign focused on amyotrophic lateral sclerosis (ALS) during ALS...

Next Page keyboard_arrow_right